| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Zymostenol targets retinoic acid receptor-related orphan receptor γ (RORγ), a nuclear receptor that plays a key role in the regulation of immune responses, particularly in the differentiation of Th17 cells. As an agonist, Zymostenol activates RORγ, which can modulate the transcription of target genes involved in inflammation and immune function.
|
|---|---|
| ln Vitro |
Zymostenol (12-104 μM) stimulates the development of myelinated collagen (MBP+) oligoastrocytes in progenitors of mouse ectodermal stem cells [2]. 20 μM Zymostenol for three days.
In vitro, Zymostenol acts as an agonist of RORγ with an EC50 value of 1 µM in a RORγ coactivator recruitment assay in the presence of ursolic acid. Its activity is assessed using cell-based reporter assays or biochemical assays measuring RORγ-mediated transcription. |
| ln Vivo |
In vivo activity data for Zymostenol are limited in the available literature. As a late-stage precursor in cholesterol biosynthesis and a RORγ agonist, it has potential applications in studying cholesterol metabolism and immune regulation. Further in vivo studies are needed to characterize its biological effects.
|
| Enzyme Assay |
In vitro receptor binding or activation assays for Zymostenol are performed using RORγ protein. The compound's ability to recruit coactivators to RORγ is measured in a biochemical assay, and the EC50 (1 µM) is calculated from the concentration-response curve. These assays quantify the compound's potency as a RORγ agonist.
|
| Cell Assay |
Cell cycle analysis [2]
Cell Types: MCF-7 Cell Tested Concentrations: 20 µM Incubation Duration: 3 days Experimental Results: Induced 67 ± 1% cell accumulation) Place MCF-7 cell cycle in G0-G1 phase [3]. G0-G1 phase of the cell cycle. In vitro cellular assays for Zymostenol are performed using cells expressing RORγ, such as immune cells or reporter cell lines. Cells are treated with the compound, and RORγ-mediated transcription is measured using reporter gene assays or by quantifying the expression of RORγ target genes (e.g., IL-17) using qRT-PCR. |
| Animal Protocol |
In vivo animal experiments for Zymostenol are not extensively documented in the available literature. As a research compound, in vivo studies would typically involve administration to animal models of immune-mediated diseases. The compound would be administered via appropriate routes, and efficacy would be assessed by measuring inflammatory markers and disease severity.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of Zymostenol have not been systematically characterized. The compound has a molecular weight of 386.65, molecular formula C27H46O, and a purity of >98%. It is soluble in DMF (3 mg/mL) and ethanol (2 mg/mL). It should be stored at -20°C.
|
| Toxicity/Toxicokinetics |
Toxicological data for Zymostenol are not extensively reported. As a research-use compound, its safety profile has not been formally evaluated in comprehensive preclinical toxicology studies. The compound is intended for research purposes only and is not approved for human therapeutic use. Standard laboratory safety precautions should be followed when handling this compound.
|
| References |
|
| Additional Infomation |
5α-Cholesterol-8-en-3β-ol is a cholesterol compound formed by replacing the β-hydroxyl group at the 3-position of 5α-cholestane. It is a metabolite in both humans and mice. It is a 3β-sterol and a cholesterol compound. It is derived from the hydride of 5α-cholestane. Zimosol has been reported to be detected in marine algae (Chattonella marina), humans (Homo sapiens), and cannabina (Axinella cannabina), and relevant data are available for reference.
Zymostenol is also known as 5α-Cholest-8-en-3β-ol and Δ8-Cholesterol. It is a late-stage precursor in cholesterol biosynthesis and a RORγ agonist with an EC50 of 1 µM. This product is for research use only. |
| Molecular Formula |
C27H46O
|
|---|---|
| Molecular Weight |
386.664
|
| Exact Mass |
386.355
|
| CAS # |
566-97-2
|
| Related CAS # |
Zymostenol-d7;2260669-19-8
|
| PubChem CID |
101770
|
| Appearance |
White to off-white solid powder
|
| LogP |
7.532
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
28
|
| Complexity |
603
|
| Defined Atom Stereocenter Count |
7
|
| SMILES |
C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CCC3=C2CC[C@@H]4[C@@]3(CC[C@@H](C4)O)C)C
|
| InChi Key |
QETLKNDKQOXZRP-XTGBIJOFSA-N
|
| InChi Code |
InChI=1S/C27H46O/c1-18(2)7-6-8-19(3)23-11-12-24-22-10-9-20-17-21(28)13-15-26(20,4)25(22)14-16-27(23,24)5/h18-21,23-24,28H,6-17H2,1-5H3/t19-,20+,21+,23-,24+,26+,27-/m1/s1
|
| Chemical Name |
(3S,5S,10S,13R,14R,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,5,6,7,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol
|
| Synonyms |
Δ8-Cholesterol; Zymostenol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5863 mL | 12.9313 mL | 25.8625 mL | |
| 5 mM | 0.5173 mL | 2.5863 mL | 5.1725 mL | |
| 10 mM | 0.2586 mL | 1.2931 mL | 2.5863 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
